Birchview Capital, LP’s Stoke Therapeutics Inc Position
Does Birchview Capital, LP own Stoke Therapeutics Inc (STOK)? Yes — 210.0K shares worth $7M (+3.89% of its 13F portfolio) as of Q1 2026, down from 260.0K shares the prior filed quarter.
Position Value
$7M
Q1 2026
Shares
210.0K
% of Portfolio
+3.89%
Quarters Held
25
currently held
Position History STOK
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 210.0K | $7M | +3.89% |
| Q4 2025 | 260.0K | $8M | +4.83% |
| Q3 2025 | 210.0K | $5M | +3.73% |
| Q2 2025 | 210.0K | $2M | +2.37% |
| Q1 2025 | 210.0K | $1M | +1.21% |
| Q4 2024 | 210.0K | $2M | +1.89% |
| Q3 2024 | 210.0K | $3M | +2.24% |
| Q2 2024 | 210.0K | $3M | +2.63% |
| Q1 2024 | 210.0K | $3M | +2.31% |
| Q4 2023 | 210.0K | $1M | +0.87% |
| Q3 2023 | 85.0K | $334,900 | +0.29% |
| Q2 2023 | 85.0K | $903,550 | +0.68% |
| Q1 2023 | 15.0K | $125 | +0.10% |
| Q4 2022 | 15.0K | $138 | +0.10% |
| Q3 2022 | 15.0K | $193,000 | +0.14% |
| Q2 2022 | 15.0K | $198,000 | +0.14% |
| Q1 2022 | 15.0K | $316,000 | +0.23% |
| Q4 2021 | 15.0K | $360,000 | +0.23% |
| Q3 2021 | 15.0K | $382,000 | +0.26% |
| Q2 2021 | 15.0K | $505,000 | +0.30% |
| Q1 2021 | 15.0K | $583,000 | +0.35% |
| Q4 2020 | 20.0K | $1M | +0.71% |
| Q3 2020 | 20.0K | $670,000 | +0.45% |
| Q2 2020 | 20.0K | $477,000 | +0.29% |
| Q1 2020 | 20.0K | $458,000 | +0.41% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Birchview Capital, LP’s full portfolio or all institutional holders of STOK.